Adjuvant therapy of malignant melanoma

Surgical Oncology Clinics of North America

Volumn 6, Issue 4, 1997, Pages 793-812

  Dickler, M N ^a   Coit, D G ^a   Meyers, M L ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; BCG VACCINE; CANCER VACCINE; CISPLATIN; DACARBAZINE; GAMMA INTERFERON; INTERLEUKIN 2; LEVAMISOLE; MONOPHENOL MONOOXYGENASE; VINBLASTINE; VINDESINE;

ANTIBODY RESPONSE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW SUPPRESSION; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; DRUG MEGADOSE; FLU LIKE SYNDROME; HUMAN; IMMUNOMODULATION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LYMPH NODE BIOPSY; LYMPH NODE METASTASIS; MELANOMA; PATIENT SELECTION; QUALITY OF LIFE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; VACCINATION;

EID: 0030693124     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1055-3207(18)30304-1     Document Type: Review

References (58)

1. Albertini J.J. Cruse C.W. Rapaport D. Intraoperative radiolymphoscintigraphy improves sentinel lymph node identification for patients with melanoma Ann Surg 223 1996 217 224
2. Aranha G.V. McKhann C.F. Grage T.B. Adjuvant immunotherapy of malignant melanoma Cancer 43 1979 1297 1303
3. Balch C.M. Murray D.M. Presant C. Ineffectiveness of adjuvant chemotherapy using DTIC and cyclophosphamide in patients with resectable metastatic melanoma Surgery 95 1984 454 458
4. Balch C.M. Reintgen D.S. Kirkwood J.M. Cutaneous melanoma DeVita V.T. Hell-man S. Rosenberg S.A. Cancer: Principles and Practice of Oncology ed 5 1997 Lippincott-Raven Philadelphia 1947 1994
5. Balch C.M. Soong S-J Bartolucci A.A. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger Ann Surg 224 1996 255 266
6. Banzet P. Jacquillat C. Civatte J. Adjuvant chemotherapy in the management of primary malignant melanoma Cancer 41 1978 1240 1248
7. Berd D. Maguire H.C. Jr. Hart E. Post-surgical adjuvant therapy of melanoma with a dinitrophenyl (DNP)-conjugated vaccine: Prolongation of disease-free and total survival Proc Am Soc Clin Oncol 12 1993 387
8. Berd D. Maguire H.C. Jr. McCue P. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: Clinical and immunologic results in 64 patients J Clin Oncol 8 1990 1858 1867
9. Berd D. Maguire H.C. Jr. Nathan F.N. Autologous, DNP-modified vaccine as post-surgical adjuvant treatment of stages III and IV melanoma Proc Am Soc Clin Oncol 15 1996 554
10. Buzaid A.C. Legha S. Bedikian A. Neoadjuvant biochemotherapy in melanoma patients with local regional metastases Proc Am Soc Clin Oncol 15 1996 434
11. Buzaid A.C. Ross M.I. Balch C.M. Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system J Clin Oncol 15 1997 1039 1051
12. Bystryn J.C. Oratz R. Roses D. Relationship between immune response to melanoma vaccine immunization and clinical outcome in stage II malignant melanoma Cancer 69 1992 1157 1164
13. Cascinelli N. Evaluation of efficacy of adjuvant rIFN-α-2a in melanoma patients with regional node metastases Proc Am Soc Clin Oncol 14 1995 410
14. Cascinelli N. Bufalino R. Morabito A. Results of adjuvant interferon study in WHO melanoma programme Lancet 343 1994 913 914
15. Cassel W.A. Murray D.R. Phillips H.S. A phase II study on the postsurgical management of stage II malignant melanoma with a Newcastle Disease virus oncolysate Cancer 52 1983 856 860
16. Coit D. Sauven P. Brennan M. Prognosis of thick cutaneous melanoma of the trunk and extremity Arch Surg 125 1990 322 326
17. Cole B.F. Gelber R.D. Kirkwood J.M. Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: An Eastern Cooperative Oncology Group study J Clin Oncol 14 1996 2666 2673
18. Cole D.J. Baron P.L. Surgical management of patients with intermediate thickness melanoma: Current role of elective lymph node dissection Semin Oncol 23 1996 719 724
19. Creagan E.T. Dalton R.J. Ahmann D.L. Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma J Clin Oncol 13 1995 2776 2783
20. Elias E.G. Buda B. Fabian D.F. Low dose cyclophosphamide and irradiated autologous tumor cells as adjuvant to surgery Proc Am Soc Clin Oncol 12 1993 387
21. Fisher R.I. Terry W.D. Hodes R.J. Adjuvant immunotherapy or chemotherapy for malignant melanoma Surg Clin North Am 61 1981 1267 1277
22. Grob J.J. Dreno B. Delaunay M. Results of the French multicenter trial on adjuvant therapy with interferon alfa-2a in resected primary melanoma (>1.5 mm) Proc Am Soc Clin Oncol 15 1996 437
23. Hedley D.W. McElwain T.J. Currie G.A. Specific active immunotherapy does not prolong survival in surgically treated patients with stage IIB malignant melanoma and may promote early recurrence Br J Cancer 37 1978 491 496
24. Helling F. Zhang S. Shang A. GM2-KLH conjugate vaccine: Increased immuno-genicity in melanoma patients after administration with immunological adjuvant QS-21 Cancer Res 55 1995 2783 2788
25. Hersey P. Active immunotherapy with viral lysates of micrometastases following surgical removal of high risk melanoma World J Surg 16 1992 251 260
26. Hill G.J. II Moss S.E. Golomb F.M. DTIC and combination therapy for melanoma: DTIC (NSC 45388) surgical adjuvant study COG protocol 7040 Cancer 47 1981 2556 2562
27. Houghton A.N. Meyers M.L. Chapman P.B. Medical treatment of metastatic melanoma Surg Clin North Am 76 1996 1343 1354
28. Jones P.C. Sze L.L. Liu P.Y. Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen J Natl Cancer Inst 66 1981 249 254
29. Karakousis C.P. Didolkar M.S. Lopez R. Chemoimmunotherapy (DTIC and Cory-nebacterium parvum) as adjuvant treatment in malignant melanoma Cancer Treat Rep 63 1979 1739 1743
30. Kassas H.E. Kirkwood J.M. Adjuvant application of interferons Semin Oncol 23 1996 737 743
31. Kirkwood J.M. Strawderman M.H. Ernstoff M.S. Interferon alpha-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684 J Clin Oncol 14 1996 7 17
32. Lejeune F.J. Macher E. Kleeberg U. An assessment of DTIC versus levamisole or placebo in the treatment of high risk stage I patients after surgical removal of a primary melanoma of the skin. A phase III adjuvant study. EORTC protocol 18761 Eur J Cancer Clin Oncol 24 1988 S81 S90
33. Livingston P.O. Wong G.Y.C. Adluri S. Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside J Clin Oncol 12 1994 1036 1044
34. Loutfi A. Shakr A. Jerry M. Double blind randomized prospective trial of levami-sole/placebo in stage I cutaneous malignant melanoma Clin Invest Med 10 1987 325 328
35. McIllmurray M.B. Embleton M.J. Reeves W.G. Controlled trial of active immunotherapy in management of stage IIB malignant melanoma Br Med J 1 1977 540 542
36. McIllmurray M.B. Reeves W.G. Langman M.J.S. Active immunotherapy in malignant melanoma Br Med J 1 1978 579 letter
37. Meisenberg B.R. Ross M. Vredenburgh J.J. Randomized trial of high-dose chemotherapy with autologous bone marrow support as adjuvant therapy for high-risk, multinode-positive malignant melanoma J Natl Cancer Inst 85 1993 1080 1085
38. Mellado B. Colomer D. Castel T. Detection of circulating neoplastic cells by reverse-transcriptase polymerase chain reaction in malignant melanoma: Association with clinical stage and prognosis J Clin Oncol 14 1996 2091 2097
39. Meyskens F.L. Jr. Kopecky K.J. Taylor C.W. Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: A Southwest Oncology Group study J Natl Cancer Inst 87 1995 1710 1713
40. Miller K. Abeles G. Oratz R. Improved survival of patients with melanoma with an antibody response to immunization to a polyvalent melanoma vaccine Cancer 75 1995 495 502
41. Mitchell M.S. Spears L. Deans G. Effect of a melanoma lysate vaccine on survival in minimal residual melanoma [abstract 1331] Proc Annu Meet Am Assoc Cancer Res 36 1995 223
42. Morton D.L. Barth A. Vaccine therapy for malignant melanoma Ca Cancer J Clin 46 1996 225 244
43. Morton D.L. Davtyan D.G. Wanek L.A. Multivariate analysis of the relationship between survival and the microstage of primary melanoma by Clark level and Breslow thickness Cancer 71 1993 3737 3743
44. Morton D.L. Foshag L.J. Hoon D.S.B. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine Ann Surg 216 1992 463 482
45. Morton D.L. Wanek L. Nizze J.A. Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes: Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic Ann Surg 214 1991 491 501
46. Morton D.L. Wen D-R. Wong J.H. Technical details of intraoperative lymphatic mapping for early stage melanoma Arch Surg 127 1992 392 399
47. Parker S.L. Tong T. Bolden S. Cancer statistics, 1997 Ca Cancer J Clin 47 1997 5 27
48. Quirt I.C. Shelley W.E. Pater J.L. Improved survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole: A phase III study by the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 9 1991 729 735
49. Reintgen D.S. Conrad A.J. Detection of occult melanoma cells in sentinel lymph nodes and blood Semin Oncol 24 1997 S4-11 S4-15
50. Retsas S. Quigley M. Pectasides D. Clinical and histologic involvement of regional lymph nodes in malignant melanoma Cancer 73 1994 2119 2130
51. Rigel D.S. Malignant melanoma: Perspectives on incidence and its effects on awareness, diagnosis, and treatment Ca Cancer J Clin 46 1996 195 198
52. Rigel D.S. Friedman R.J. Kopf A.W. The incidence of malignant melanoma in the United States: Issues as we approach the 21st century J Am Acad Dermatol 34 1996 839 847
53. Spitler L.E. A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma J Clin Oncol 9 1991 736 740
54. Spitler L.E. Sagebiel R. A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma N Engl J Med 303 1980 1143 1147
55. Tranum B.L. Dixon D. Quagliana J. Lack of benefit of adjunctive chemotherapy in stage I malignant melanoma: A Southwest Oncology Group study Cancer Treat Rep 71 1987 643 644
56. Veronesi U. Adamus J. Aubert C. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma N Engl J Med 307 1982 913 916
57. Wallack M.K. Sivanandham M. Balch C.M. A phase III randomized, double-blind, multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma Cancer 75 1995 34 42
58. Wood W.C. Cosimi A.B. Carey R.W. Randomized trial of adjuvant therapy for “high risk” primary malignant melanoma Surgery 83 1978 677 681